The forecast for Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Germany is expected to remain relatively stable, with 98 cases projected for 2024, 2025, and 2026, and a slight increase to 99 cases in 2027 and 2028. This indicates minimal growth, with no significant year-on-year variation. Historical data show these numbers are consistent with recent trends. The Compound Annual Growth Rate (CAGR) over these five years is nearly negligible. In 2023, the number of cases was approximately the same as in 2024, confirming this stability in resistance levels.
Future trends to watch for include advancements in tuberculosis treatment and diagnostics, as potential breakthroughs could curtail resistance rates. Monitoring public health policies and efforts to control TB transmission will also be crucial in predicting future case numbers. Additionally, global economic and migratory trends may influence TB resistance dynamics in Germany.
